Rexigo 120mg (Relugolix)

Rexigo 120mg (Relugolix) Overview

Rexigo is a brand name for Relugolix, an oral medication classified as a gonadotropin-releasing hormone (GnRH) receptor antagonist. It is commonly used for the treatment of hormonally sensitive conditions, including prostate cancer, which is in advanced stages. Stopping GnRH receptors, it decreases testosterone production. a hormone that is responsible for the growth of some cancers.

What is Relugolix?

Relugolix is an original oral GnRH antagonist that works through direct inhibition of the GnRH receptors located in the pituitary gland. This rapidly inhibits the production of luteinizing hormone (LH) as well as follicle-stimulating hormone (FSH) that results in a decrease in the production of testosterone by the testes.

Indications and Uses

Rexigo 120 mg (Relugolix) is primarily indicated for:

• Advanced prostate cancer: Utilized to decrease testosterone levels in men who have prostate cancers that are hormone sensitive. By reducing testosterone levels, you can stop the growth of cancer.
• Other hormone-sensitive conditions: The drug can also be researched or taken off-label, in which suppression of sexual hormones is a goal.

Mechanism of Action

Relugolix works as a competitive antagonist to the GnRH receptors located in the pituitary gland. Blocking these receptors, it stops GnRH from producing LH as well as FSH. LH boosts testosterone production in the testes. Its decrease causes fast and long-lasting drops in testosterone levels. The process is called medical castration.

In contrast to GnRH antagonists, which initially trigger the testosterone levels to rise before reduction, GnRH antagonists like Relugolix can avoid the flare effect by allowing for a more immediate and effective control of the hormone levels.

Dosage and Administration

• Dosage: The recommended dose for Rexigo is 120 mg, taken in a daily dose.
• Administration: It is recommended to take it in the same way every day, whether with or without food.
• Duration: The length of treatment depends on the condition of the patient as well as the doctor’s opinion, and is typically extended until the benefit has been evident or until adverse reactions require the discontinuation of treatment.

Patients are required to adhere to the regimen prescribed for a consistent suppression of testosterone.

Benefits of Rexigo (Relugolix)

• Oral administration: In contrast to other hormone treatments, which require injections, Rexigo can be taken as an oral tablet, which offers ease of use.
• Rapid testosterone suppression: It is a way to avoid the initial surge of testosterone that occurs in other treatments.
• Reduced risk of flare symptoms: There is no flare-related increase in prostate cancer signs.
• Improved cardiovascular safety: Certain studies indicate that Relugolix could offer a superior cardiovascular rating compared with traditional GnRH antagonists.

Side Effects and Adverse Reactions

Common side effects include:

• Hot flashes
• Fatigue
• Headache
• Diarrhea
• Constipation
• Muscle pain or weakness
• Increased risk of bone thinning (osteoporosis)
• Decreased libido and erectile dysfunction

Less common but serious side effects:

• Cardiovascular events: While Relugolix might be more effective, however, those with heart diseases should be closely checked.
• Severe allergic reactions: Rare.
• Liver function abnormalities: If clinically recommended, monitor the patient.

Precautions and Contraindications

• Pregnancy and women: Rexigo is not recommended for women who may or are about to get pregnant due to the possibility of damage to the embryo.
• Bone Health: A prolonged suppression of testosterone may result in a decrease in bone mineral density. Monitoring and preventive measures are suggested.
• Cardiovascular Risk: Patients suffering from heart disease must be assessed cautiously.
• Liver Function: Beware of patients suffering from liver impairment.
• Drug Interactions: Patients must inform their healthcare doctors about any medications they take since interactions could be observed.

Monitoring

Patients of Rexigo require monitoring regularly, which includes:

• Testosterone levels: To ensure adequate suppression.
• Prostate-specific antigen (PSA): For assessing the level of cancer prevention.
• Bone mineral density: Particularly for long-term treatment.
• Cardiovascular status: Watching for indicators of heart condition.
• Liver function tests: If indicated.

Summary

Rexigo 120 mg (Relugolix) is an efficient oral GnRH antagonist, which is primarily used in advanced prostate cancers to quickly suppress testosterone production. The oral route of administration and the absence of flare-ups with testosterone make it a desirable alternative to injectable GnRH antagonists. Although generally tolerated, patients must be monitored for any adverse effects, particularly those related to cardiovascular health or bone density.

Patients must follow the medical advice with strictness, keep regular appointments, and notify any abnormal symptoms immediately.